MSK Research Highlights, September 4, 2025
New MSK research shows the Make-an-IMPACT program improves global access to genomic testing in pediatric cancer patients; helped develop an experimental antibody that shows promise against metastatic cancer; sheds light on the origins of ERG-driven prostate cancer; and finds Dupilumab is a successful agent to treat skin toxicities related to antibody-drug conjugates.